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Abstract: The overall purpose of hypertension treatment is 2-fold. First, patients often have 
symptoms that are related to their high blood pressure and although subtle in many instances 
may be improved dramatically by blood pressure control. The main reason for blood pressure 
treatment, however, is to reduce the burden of cardiovascular complications and end organ 
damage related to the condition. This may be considered the ultimate goal of blood pressure 
treatment. In this respect, actual blood pressure measurements may be seen as surrogate end 
points as the organ protective effects of two antihypertensive agents may differ signifi cantly 
even though their blood pressure lowering effects are similar. Thus beta-blockers, once seen 
as fi rst-line treatment of hypertension for most patients, now are considered as third- or fourth-
line agents according to the latest NICE guidelines (National Institute for Health and Clinical 
Excellence, www.nice.org.uk/CG034). On the other hand, agents that inhibit the activity of the 
renin-angiotensin-aldosterone system (RAAS) system are being established as safe, effective 
and end organ protective in numerous clinical trials, resulting in their general acceptance as 
fi rst-line treatment in most patients with stage 2 hypertension. This shift in emphasis from beta-
blockers and thiazide diuretics is supported by numerous clinical trials and has proven safe and 
well tolerated by patients. The impact of this paradigm shift will have to be established in future 
long-term randomized clinical trials. The optimal combination treatment with respect to end 
organ protection has yet to be determined. Most combinations will include either a RAAS active 
agent and calcium channel blocker or two separate RAAS active agents working at different 
levels of the cascade. In this respect direct renin inhibitors and angiotensin receptor blockers 
seem particularly promising but the concept awaits evaluation in upcoming randomized clinical 
trials. Although safety data from the randomized clinical trials to date have been promising, we 
still lack data on the long-term effect of aliskiren on mortality and there still are patient groups 
where the safety of aliskiren is unexplored.
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Introduction
High blood pressure is a major risk factor for stroke, myocardial infarction, heart failure, 
peripheral artery disease and renal failure.1–3 The global prevalence of hypertension is 
believed to be 25% to 30% in the adult population and is steadily increasing in western 
societies.4–6 Among the elderly (65 years) the prevalence of hypertension is even 
higher, reaching 50% to 70%7 and is an increasing public health concern.8 The condition 
confers a 3- to 4-fold increased risk of cardiovascular disease and renal failure and is 
associated with declining cognitive function among the affected.9
There is a continuous independent relationship between elevated systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) and stroke and cardiovascular 
mortality for all age groups. The mortality risk is doubled for every 20 mmHg rise 
in SBP and 10 mmHg rise in DBP from the level of 115/75 mmHg.10 Based on the 
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steadily increasing proportion of elderly in the population, 
it can be predicted that cardiovascular and renal complica-
tions of high blood pressure will increase even further in 
the coming decades unless appropriate preventive measures 
are taken.
In an attempt to attenuate the dire complications of hyper-
tension, clinicians are faced with an array of antihypertensive 
agents. In many instances, the older generic drugs have been 
found as effective for blood pressure lowering as the newly 
developed antihypertensive agents. However, only recently 
randomized clinical trials have provided insight into the rela-
tive effi cacy of these agents to confer end organ protection 
which may be seen as the ultimate goal of blood pressure 
treatment. Selection of antihypertensive treatment needs to be 
based on the presumed clinical benefi t that may be obtained 
for different patient groups. In this context health care pro-
viders will increasingly rely on randomized clinical trials to 
tailor treatment alternatives to each individual patient. This 
review will focus on treatment of hypertension in the elderly 
population with special reference to the value of agents act-
ing on the renin-angiotensin-aldosterone system (RAAS) 
including the direct renin inhibitor (DRI) aliskiren.
Hypertension in the elderly
With advancing age the aorta and medium size arterioles 
become calcifi ed and lose elasticity. This process is depen-
dent on age-related changes of elastin fi bres in the media, 
proliferation of collagen and deposition of calcium. The 
resulting arteriosclerosis causes a rise in peripheral vascular 
resistance and elevated SBP but also a fall in DBP and con-
sequently, a high pulse pressure. The changes in the vascular 
tree that occur with advancing age are rather complicated 
and include, apart from calcifi cation, humoral changes and 
vascular hypertrophy. This results in a continuous rise in SBP 
throughout adult life, whereas DBP peaks at about 60 years 
of age and declines thereafter. The resulting rise in pulse 
pressure with advancing age has been used as a predictor of 
adverse cardiovascular outcome.11,12
Aortic stiffness, measured by carotid-femoral pulse wave 
velocity, increases the risk of cardiovascular mortality, coro-
nary events and fatal strokes among the elderly.13,14 This risk 
factor becomes more important in patients over 50 years of 
age.11 The proportion of elderly subjects is steadily growing in 
industrialized countries and is expected to reach a quarter of 
the US population by year 2035.15 The prevalence of isolated 
systolic hypertension in this age group is over 65%16 and the 
lifetime risk of developing hypertension exceeds 90%. The 
importance of blood pressure control in this age group has 
been confi rmed by several interventional trials.17–19 In spite 
of these facts, only 20% of elderly hypertensives have blood 
pressure controlled to values below 140/90 mmHg.
This may have a serious impact in the overall health of 
elderly people causing cardiovascular disease, heart failure, 
stroke, renal failure and reduced quality of life.
The RAAS in hypertension
The RAAS plays a central role in the regulation of blood 
pressure (Figure 1). Renin, an aspartic protease, is generated 
and released by the juxtaglomerular cells in the kidney. It 
has one known substrate, angiotensinogen, and catalyzes the 
conversion of angiotensinogen to angiotensin I (Ang I) in the 
rate limiting step of the cascade. Formation of Ang I is favored 
by a 5000-fold concentration gradient. The decapeptide Ang I 
is then converted to the octapeptide angiotensin II (Ang II) 
by angiotensin-converting enzyme (ACE). The Ang II thus 
formed acts on receptors of Ang II (AT-1 receptors) to 
raise blood pressure through several mechanisms. Most 
importantly, Ang II is a powerful vasoconstrictor, it stimulates 
the release of aldosterone from the adrenal cortex and 
subsequently leads to sodium reabsorbtion in the kidney and 
catecholamine release from the adrenal medulla. Hypertension 
can be caused by pathologic activation of the RAAS, leading 
to salt and water reabsorbtion, vasoconstriction and increased 
catecholamine release.
Recently, the discovery of the (pro)renin receptor has 
changed our understanding of how the RAAS system is 
involved in end organ damage.20 Pro-renin is a precursor 
to renin which has a 43 amino acid N-terminus overlying 
the enzymatic cleft of the renin molecule, thus rendering it 
inactive. Pro-renin is much more abundant than renin in the 
circulation and its concentration is especially high in diabet-
ics. Pro-renin can be activated both by proteolytic and non-
proteolytic pathways. The proteolytic pathway takes place 
in the juxtaglomerular apparatus in the kidney where the 
43 amino acid N-terminus is removed and leaves the active 
renin molecule. Non-proteolytic activation of pro-renin takes 
place by binding to the (pro)renin receptor. Pro-renin thereby 
becomes enzymatically active without losing its N-terminus 
and this binding increases its emzymatic activity 4- to 5-fold. 
The activation of pro-renin leads to Ang II production locally 
at the cell surface where it is in close vicinity with ACE and 
the AT-1 receptor. At the tissue level renin and pro-renin also 
have physiologic effects through the (pro)renin receptor that 
are completely independent of Ang II production. Intracel-
lular signaling pathways cause upregulation of pro-fi brotic 
mediators that lead to contractility disturbances, hypertrophy, 
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fi brosis and apoptosis. This is a potential second target for 
control of the RAAS with renin inhibitors that might lead to 
organ protection beyond the blood pressure lowering effects 
achieved by ACE-inhibitors (ACE-I) and angiotensin recep-
tor blockers (ARBs).
Inhibition of the RAAS has long been the target of 
pharmacological blood pressure regulation. Inhibitors of 
the ACE reduce the production of Ang II and have been 
proven to be effective blood pressure lowering agents. Their 
effectiveness is, however, hampered by the ACE-independent 
pathways of chymases and dipeptidases that are found in end 
organs such as the heart, blood vessels and kidneys. Thus, 
Ang II can still be produced by these pathways in spite of 
effective ACE-I. In addition, ACE-I often have side affects 
including cough that is thought to result from the accumula-
tion of bradykinin and substance P due to the blockage of 
their breakdown.
Another target of RAAS inhibition is blockade of the 
AT-1 receptor by ARBs. Other receptors of Ang II such as 
AT-2 and AT-4 are not affected, but the clinical effect of 
their unopposed stimulation is not fully understood. This 
may include infl ammatory and fi brotic responses leading 
to vascular damage and left ventricular hypertrophy. Both 
ACE-I and ARBs attenuate the negative feedback loop of 
Ang II on renin production and thus increase both renin 
concentration and plasma renin activity.
Direct renin inhibition (DRI) is a new concept in the 
treatment of hypertension.21 The prototype compound 
aliskiren is a small-molecular-weight, orally active, 
non-peptide that has high affi nity for the active site on the 
renin molecule. Although the bioavailability of aliskiren is 
rather low after oral administration (2.5%), its high affi nity 
and specifi city for the renin molecule and plasma half-life of 
24 to 36 hours makes it suitable for once-daily dosage. Similar 
to other blockers of the RAAS and thiazide diuretics, aliskiren 
increases plasma renin concentration (PRC). However, in 
contrast to other drug classes acting on the RAAS, the plasma 
renin activity (PRA) is effectively blocked by aliskiren. The 
potential benefi t of DRI on end organ protection might also 
be related to Ang II independent effects of renin on the tissue 
level. Thus DRIs might not only inhibit the conversion of 
angiotensin to Ang I, both in the circulation and tissue level, 
but also blunt intracellular pathways of end organ damage 
induced directly by receptor bound (pro)renin.22
Treatment of hypertension 
in the elderly
Although previously thought to be of limited value or even 
harmful, it has now become evident from several random-
ized clinical trials and meta-analyses that treatment of 
hypertension in the elderly may reduce stroke and heart 
failure rates and even have a mortality effect.23,24 The main 
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Figure 1 The renin-angiotensin-aldosterone system and points of pharmacological intervention.
Abbreviations:  ACE, angiotensin converting enzyme;  Ang I, angiotensin I;  Ang II, angiotensin II;  ARB, angiotensin receptor blocker;  AT1, angiotensin type 1 receptor.
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goal of hypertension treatment is to reduce or prevent 
cardiovascular and renal disease. There is especially high 
risk for such complications in the elderly population. The 
increased risk of debilitating stroke caused by high SBP 
is a major concern among elderly hypertensives and needs 
to be treated aggressively, as stroke has a major impact 
on quality of life and life expectancy of these patients.25–27 
According to current ESH-ESC Guidelines on management 
of hypertension28 and several clinical trials, elderly patients 
benefi t from antihypertensive therapy in terms of reduced 
cardiovascular morbidity18,29–32 and mortality.24
Although elevated blood pressure has been the subject of 
intensive clinical and experimental studies through the last 
5 decades and an arsenal of effective and safe antihyperten-
sive medication is available, we still are far from achieving 
acceptable control rates. The results of the Euroaspire III 
study presented at the European Congress of Cardiology 
in Munich 200833 showed that in spite of increased use of 
antihypertensive medication, the control rate of hyperten-
sion had not improved and 61% of patients were above the 
therapeutic target of 140/90 mmHg.
Non-pharmacological treatment
Life style modifi cation with weight loss and reduced salt 
intake are of particular value in the elderly because most 
of these patients are obese and salt sensitive. In the Trial of 
Nonpharmacologic Interventions in the Elderly (TONE), 
sodium intake was reduced to 80 mmol (2 g) per day and 
resulted in a modest reduction in SBP and DBP and 40% 
of the treated patients were able to discontinue previous 
medication.34 In this study, additional blood pressure lower-
ing was seen when weight loss was added to salt restriction. 
Life style modifi cation in the elderly should also encourage 
physical activity.
Pharmacological treatment
Pharmacological treatment of hypertension in the elderly 
follows the same general principles that are laid out in the 
current guidelines6,28 and taking into consideration individual 
compelling indications for specifi c drug classes.35–39 How-
ever, in the elderly population these recommendations are 
based on a limited number of clinical trials. Bearing in mind 
the increased variability in blood pressure among elderly 
hypertensives, their reduced cardiovascular sensitivity to 
catecholamine stimulation and tendency to postural hypoten-
sion, care should be taken to initiate drug therapy with low 
doses and titrate up to effective doses according to individual 
response. As with hypertension in general, the elderly are 
likely to need two or more different medications in order to 
control their blood pressure.
Although it is no longer disputed that effective blood 
pressure treatment leads to considerable reduction in 
cardiovascular disease in general and stroke risk in particular, 
there is still uncertainty of whether specifi c classes of blood 
pressure lowering agents confer a greater benefi t than others 
in end organ protection.40
Placebo-controlled trials
In the Swedish Trial in Old Patients with Hypertension29 
1627 hypertensive patients 70 to 84 years of age were 
randomized in a double blind fashion to treatment with 
beta-blockers or thiazide diuretic vs placebo. The entry blood 
pressure criteria were SBP between 180 and 230 mmHg with 
a diastolic pressure of at least 90 mmHg, or a DBP between 
105 and 120 mmHg irrespective of the systolic pressure. The 
mean difference in blood pressure levels between treatment 
arms was 19.5/8.1 mmHg after an average of 25 months 
of treatment. In this trial the SBP lowering effect of the 
thiazide was more pronounced than that of the beta-blockers. 
The primary end point of stroke, myocardial infarction and 
cardiovascular death was signifi cantly reduced by 38% 
(p = 0.0031), stroke rate was reduced by 45% (p = 0.0081) 
and there was also a signifi cant reduction in death rate among 
the actively treated patients. This study established that mor-
bidity and mortality reductions can be achieved in elderly 
hypertensives with active blood pressure lowering treatment 
based on beta-blockers or thiazide diuretics.
The European Working Party on High Blood Pressure 
in the Elderly trial41 was a double-blind, placebo controlled 
trial of diuretic based (hydrochlorothiazide + triamterene) 
treatment vs placebo in hypertensive subjects, 60 years or 
older with entry blood pressure levels of 160 to 239 mmHg 
systolic and 90 to 119 mmHg diastolic. Methyldopa could 
be added to the active treatment group in case of suboptimal 
blood pressure control. The results showed no signifi cant 
reduction in total mortality by active treatment (9%, p = 0.41), 
but a signifi cant reduction in cardiovascular mortality (27%, 
p = 0.037) that was mainly driven by a 38% reduction in 
cardiac mortality (p = 0.036).
The Systolic Hypertension in the Elderly Program 
(SHEP)18 was a clinical trial where 4736 elderly subjects with 
stage 2 isolated systolic hypertension (systolic  160 mmHg, 
diastolic  90 mmHg) were randomized to treatment with 
a thiazide type diuretic (chlorthalidone) or placebo. In the 
active treatment arm atenolol, resperine and hydralazine 
could be added to achieve blood pressure control. SBP was 
Clinical Interventions in Aging 2009:4 141
Aliskiren for hypertension in the elderly
lower in the treatment group (143 mmHg) than the control 
group (155 mmHg) and the primary end point of stroke was 
signifi cantly reduced by 36% (p = 0.0003), heart failure by 
49% and coronary events by 27%. The treatment was well 
tolerated. This was a landmark trial that showed that blood 
pressure lowering in elderly patients was not only safe, but 
also effective in reducing clinical end points.
The placebo-controlled randomized HYVET trial24 
studied 3845 hypertensive subjects over 80 years of age 
with a sustained SBP of 160 mmHg or greater. Treatment 
was initiated with a thiazide (indapamide sustained release 
1.5 mg/day) and an ACE-I (perindopril 2–4 mg/day) added 
if needed for blood pressure control (150/80 mmHg). 
The primary end point was fatal and non-fatal stroke with a 
median follow-up period of 1.8 years. The study was stopped 
prematurely by the data safety monitoring board for ethical 
reasons. The results showed a 30% reduction in the primary 
end point that was of borderline statistical signifi cance 
(p = 0.06). However, there was a convincing 39% reduction 
in stroke mortality (p = 0.05), a 21% reduction in all cause 
mortality (p = 0.02) and a 64% reduction in heart failure 
(p  0.001) at follow-up indicating that this approach to 
treat hypertensive patients 80 years or older with a thiazide 
diuretic, allowing optional combination with an ACE-I is not 
only safe, but also lowers stroke rate, heart failure and all 
cause mortality and thus confers a signifi cant clinical benefi t 
to this patient group.
These placebo-controlled trials confi rm the effi cacy of 
thiazides alone or in combinations for end organ protection 
in elderly hypertensives. This is supported by a meta-analysis 
looking at 18 placebo controlled trials of elderly hypertensive 
patients where diuretics were found to reduce stroke risk by 
51% (relative risk [RR] 0.49, 95% confi dence interval CI 
0.39–0.62) and beta-blockers by 29% (RR 0.71, 95% CI 
0.59–0.86) compared to placebo.42
The Systolic Hypertension in Europe (Syst-Eur) study,31 
elderly patients with systolic hypertension  160 mmHg, but 
diastolic 95 mmHg, were randomized to the dihydropyri-
dine calcium channel blocker nitrendipine or placebo. The 
study was stopped prematurely by the data safety monitor-
ing board because of a highly signifi cant (p = 0.003) 43% 
reduction in stroke by the calcium channel blocker. More 
surprisingly, there was also a highly signifi cant 55% reduc-
tion in dementia by the calcium channel blocker.
A large Chinese study of hypertensive patients32 60 years 
or older compared the dihydropyridine calcium channel 
blocker nitrendipine 10 to 40 mg/day, with addition of the 
ACE-I captopril 12.5 to 50 mg/day or hydrochlorothiazide 
12.5 to 50 mg/day for adequate blood pressure control 
against placebo. After 2 years of follow-up the blood pressure 
difference between placebo and active treatment groups was 
9.1/3.2 mmHg which resulted in a signifi cant reduction in 
stroke rate (38%, p = 0.01), all cause mortality (39%, p = 0.003), 
cardiovascular mortality (39%, p = 0.03), stroke mortality (58%, 
p = 0.02) and all cardiovascular end points (37%, p = 0.004) in 
the active treatment group as compared to placebo.
The Study on Cognition and Prognosis in the Elderly 
(SCOPE)43 was a randomized, study including 4964 patients 
70 to 89 years of age with stage 2 hypertension (systolic 
160–179 mmHg and or diastolic 90–99 mmHg) and a Mini 
Mental State Examination (MMSE) score of 24 or higher. 
Patients were randomized to receive the angiotensin receptor 
blocker candesartan or placebo with open label antihyperten-
sive treatment added as needed for blood pressure control. 
After a mean follow-up of 3.7 years the primary composite end 
point of cardiovascular death, non-fatal stroke, and non-fatal 
myocardial infarction was not signifi cantly different between 
treatment groups. However, non-fatal stroke was reduced by 
27.8% (p = 0.04) in the candesartan group and similarly, all 
cause stroke was reduced by 23.6% (p = 0.056). No difference 
was found between groups in myocardial infarction and 
cardiovascular mortality. There was no difference between 
treatment groups in the outcome of MMSE. Blood pressure 
was 3.2/1.6 mmHg lower in the candesartan group.
A remarkably high rate of blood pressure control was 
achieved in a randomized, placebo controlled trial using 
perindopril 2 mg combined with indapamide 0.625 mg 
as active treatment during 1 year among elderly patients 
with essential or isolated systolic hypertension.44 The mean 
blood pressure reduction was 23/13.3 mmHg and 79.8% of 
the patients achieved blood pressure control with this low 
dose combination treatment, which was well tolerated and 
equally effective in elderly (65–74 years) as in very elderly 
(75–85 years) patients.
These placebo-controlled trials of elderly patients 
with stage 2 and 3 hypertension confi rm that treatment 
of high blood pressure confers a clear benefi t in reducing 
cardiovascular mortality and morbidity in this age group. 
The agents most effective in this respect seem to be thiazide 
diuretics, calcium channel blockers and possibly ACE-I and 
ARBs although the data available for the last two classes 
are limited.
Active comparator trials
The Swedish Trial in Old Patients with Hypertension-2 
(STOP-2) study45 aimed to compare the effects of conventional 
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and newer antihypertensive drugs on cardiovascular mortality 
and morbidity in elderly patients. This was a prospective, 
randomized trial including 6614 patients, 70 to 84 years 
of age with SBP  180 mmHg and/or DBP  105 mmHg. 
The treatement in the conventional group was made up of 
beta-blockers (atenolol 50 mg, metoprolol 100 mg, pindolol 
5 mg) or the diuretic combination of hydrochlorothiazide/
amilorid 25/2.5 mg) given in a single daily dose. The 
newer drugs group was treated with an ACE-I (enalapril 
10 mg or lisinopril 10 mg) or a dihydropyridine calcium 
channel blocker (felodipine 2.5 mg or isradipine 2–5 mg) 
daily. Importantly, blood pressure was reduced similarly 
in both treatment groups, so that comparison of end points 
between treatment arms refl ects the net clinical benefi t of 
each drug over and above blood pressure lowering effi cacy. 
The primary end point was a composite of fatal stroke, fatal 
myocardial infarction and other fatal cardiovascular disease 
and occurred in almost exactly the same proportion (19.8 
events/1000 patient years) in both treatment arms (RR 0.99, 
p = 0.89). The conclusion of this trial was that the older and 
newer antihypertensive drugs tested in this trial showed simi-
lar effi cacy in preventing cardiovascular mortality and major 
events and therefore, the main importance for the prevention 
of such events would lie in the blood pressure lowering of 
these drugs rather than in the mechanism of action.
In a randomized study,46 the clinical effi cacy and toler-
ability of irbesartan 150 to 300 mg was compared to that of 
enalapril 10 to 20 mg among elderly patients with mild to 
moderate hypertension. Both agents were well tolerated, the 
only signifi cant difference being more frequent cough in the 
enalapril group. However, there was no difference in effi cacy 
between the two agents compared.
Although not primarily studies of elderly subjects, 
the patients included in the Antihypertensive and Lipid 
Lowering Treatment to Prevent Heart Attack (ALL-
HAT) trial,47 the Nordic Diltiazem study (NORDIL),48,49 
Valsartan Antihypertension Long-Term Use (VALUE)50 and 
Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure 
Lowering Arm (ASCOT-BPLA) (ASCOT) trials51 had mean 
ages  65 years of age.
The ALLHAT patients had a mean age of 67 years. This 
was a randomized clinical trial comparing chlorthalidone, the 
dihydropyridine calcium channel blocker amlodipine and the 
ACE-I lisinopril as fi rst-line therapy in hypertension. Add on 
of clonidine and reserpine was allowed for those who did not 
reach treatment target. All medications reduced prespecifi ed 
end points of cardiovascular disease similarly with the excep-
tion that heart failure rates were about 40% higher in the 
amlodipine group than for chlorthalidone. In a prespecifi ed 
subgroup of patients aged 65 years or older, combined 
coronary heart disease, combined cardiovascular disease and 
heart failure rates were signifi cantly higher with lisinopril 
than with chlorthalidone.52 Combined cardiovascular disease 
and stroke rates were also signifi cantly lower among patients 
receiving amlodipine compared with lisinopril in an elderly 
subpopulation of the ALLHAT study.53 There were no major 
differences in outcome in the elderly subgroup compared to 
the overall study population.
A subanalysis of the NORDIL study addressed the 
effect of age, sex, severity of hypertension and heart rate 
on outcome in a prospective, randomized, open label, 
blinded end point designed (PROBE) trial comparing the 
calcium channel blocker diltiazem with diuretic/beta-blocker 
based treatment.49 SBP was reduced more effectively in 
the diuretic/beta-blocker group, a difference of 3 mmHg 
(p  0.001). The primary composite end point of cardio-
vascular death, cerebral stroke and myocardial infarction 
was nevertheless similar for both treatment arms. However, 
fatal and non-fatal stroke was reduced by 20% (p = 0.04) in 
the diltiazem group with a non-signifi cant trend towards an 
increase in the rate of myocardial infarction. These results 
were more pronounced in the subgroup of patients with 
baseline SBP  170 mmHg, DBP of 105 mmHg or higher 
and pulse pressure over 65 mmHg. The favorable effect of 
the calcium channel blocker was present across all subgroups 
when analyzed according to age, sex, severity of hypertension 
and heart rate.
The ALLHAT and NORDIL studies therefore indicate 
that thiazide diuretics and calcium channel blockers might be 
more effective in stroke prevention than are ACE-I and beta- 
blockers. This is supported by a meta-analysis by Lindholm 
et al54 who found that the risk of stroke was 16% higher with 
beta-blockers than with other antihypertensive agents.
The VALUE trial50 set out to evaluate for the fi rst time 
by head-to-head comparison whether treatment with an 
ARB (valsartan) would reduce cardiac-related morbidity 
and mortality when compared with similar blood pressure 
control with the dihydropyridine calcium channel blocker 
amlodipine. The focus of this trial was on cardiac events, 
and to be eligible, patients had to have either coronary artery 
disease or be of considerable risk thereof. Effects on stroke 
rate were secondary end points in this study. As it turned out 
the mean age of the included patients was 67.2 years and 92% 
had previously treated hypertension. The mean blood pres-
sure level at study entry was 155/92 mmHg. At the time of 
the study, amlodipine was a much more frequently prescribed 
Clinical Interventions in Aging 2009:4 143
Aliskiren for hypertension in the elderly
drug than was valsartan. Consequently, a larger proportion 
of patients randomized to the amlodipine arm continued the 
medication they had been taking prior to study enrolment 
than patients randomized to the valsartan arm, most of which 
were taking the ARB for the fi st time after being previously 
treated with another antihypertensive agent. This difference 
between treatment groups probably lead to a very important 
result of the VALUE trial, that the achieved blood pressure 
in the amlodipine group was on average 4.3 mmHg lower 
than in the valsartan group in the early months, a difference 
that was still 2.2 mmHg at the end of the 5 year follow-up 
period. The study was therefore fl awed and it is diffi cult to 
draw defi nitive conclusions from the main results of the trial 
which were that there was no difference between treatment 
groups in the rate of the primary end point (myocardial 
infarction, aborted myocardial infarction or hospitalization 
for congestive heart failure).
A similar problem arose in the ASCOT-BPLA.51 This 
was a trial aiming at answering the question whether newer 
antihypertensive agents (amlodipine 5–10 mg with optional 
addition of the ACE-I perindopril 4–8 mg) were superior 
to conventional fi rst-line treatment (atenolol with optional 
addition of the thiazide diuretic bendroflumethiazide 
1.25–2.5 mg). This was a randomized double blind, trial 
that enrolled over 19,000 hypertensive patients with at least 
3 other cardiovascular risk factors. There was no difference 
between treatment groups in the primary outcome of non-
fatal myocardial infarction and fatal coronary heart disease. 
However, there was a signifi cant 23% relative reduction in 
the rate of fatal and nonfatal stroke in the amlodipine-based 
group (p = 0.0003) and a signifi cant reduction of both all 
cause (p  0.05) and cardiovascular mortality (p = 0.001) 
when the study was stopped prematurely by the data safety 
monitoring board after 5.5 years of follow-up. Much the same 
as in the VALUE trial, there was a signifi cant imbalance 
between treatment groups that was 2.7/1.9 mmHg in favor 
of the amlodipine based regimen (p  0.0001). Nevertheless, 
the authors conclude that the ASCOT trial supports the use 
of newer drugs, in multi-drug combinations, to modify risk 
factors and/or metabolic disturbances, especially in patients 
with complicated hypertension.
A more definitive conclusion can though be drawn 
from the results of the Losartan Intervention for Endpoint 
Reduction (LIFE) study.55 This was the fi st trial comparing 
two active antihypertensive medications to show a clear 
effect of one treatment arm in reducing cardiovascular 
events. The trial included patients with hypertension and left 
ventricular hypertrophy comparing the ARB losartan with 
the beta-blocker atenolol. Hydrochlorothiazide was added 
to both arms to reach treatment goals. Losartan treatment 
resulted in a 25% relative reduction in stroke compared 
with atenolol. In a substudy of patients with isolated systolic 
hypertension56 1326 patients with SBP 160 to 200 mmHg and 
DBP of less than 90 mmHg were recruited. The mean blood 
pressure at randomization was 174/83 mmHg and the mean 
age of the patients was 70 years. The primary end point was 
a composite of cardiovascular death, stroke or myocardial 
infarction. After a mean follow-up period of 4.7 years the 
primary end point was reduced by 25% by losartan treatment 
compared with atenolol (p = 0.06). After adjustment for risk 
and degree of left ventricular hypertrophy the relative risk 
reduction was 29% (p = 0.02). There was a signifi cant reduc-
tion in cardiovascular mortality (46%, p = 0.01), non-fatal 
and fatal stroke (40%, p = 0.02), new onset diabetes (38%, 
p = 0.04) and total mortality (38%, p = 0.046). Importantly, 
there was no signifi cant difference between treatment groups 
in blood pressure throughout the study. The LIFE study is 
thus a landmark trial indicating that high risk hypertensive 
and predominantly elderly patients (with or without isolated 
systolic hypertension) have a mortality and morbidity benefi t 
from treatment with losartan compared to atenolol.
These results have strongly infl uenced current international 
guidelines in that beta-blockers are no longer regarded as fi rst 
line treatment of hypertension unless compelling indication 
and co-morbidities dictate otherwise. The LIFE study is 
also remarkable for the fact that the ARB losartan seems to 
reduce the risk of stroke more than does atenolol and it was 
the fi rst trial to indicate that ARBs are in addition to calcium 
antagonists fi rst-line drugs in stroke prevention for patients 
with hypertension.
The same conclusion was drawn from the Blood Pressure 
Lowering Trialists´ Collaboration analysis57 and the JIKEI 
Heart Study58 that both confi rmed the organ protective effects 
of ARBs.
The majority of patients with type 2 hypertension will 
need combination treatment to reach treatment targets. 
Current guidelines6,28 dictate the use of combinations as 
fi rst-line treatment in these patients, of which one should be 
a thiazide diuretic. These recommendations are challenged 
by the recently published ACCOMPLISH trial results.59 
The main objective of this study was to compare the effect 
of two combination therapies on clinical end points among 
high risk patients with hypertension. These were 11,506 
patients 55 years and older with SBP 160 mmHg or higher. 
All had a history of hypertension treatment and were of high 
risk. The combinations tested were benazepril/amlodipine 
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against benazepril/hydrochlorothiazide. The data safety 
monitoring board stopped the trial early because of a 20% 
(p  0.001) lower rate of major adverse cardiac events in the 
benazepril/amlodipine combination compared to benazepril/
hydrochlorothiazide.
Taken together, the evidence from randomized clinical 
trials to date confi rm that effective blood pressure control and 
end organ protection can be achieved by any of the following 
classes of antihypertensive agents; thiazide diuretics, beta-
blockers, calcium channel antagonists, ACE-I and ARBs. 
Until recently however, clinicians have had little data to 
compare the relative effi cacy of these agents either as mono-
therapy or in various combinations. The mounting evidence 
now available challenges previous and current guidelines in 
that optimal clinical results seem to be obtainable by agents 
that block the RAAS system at different levels in combina-
tion with calcium channel blockers rather than with thiazide 
diuretics or beta-blockers. Within the RAAS cascade, com-
bination therapy is also an attractive alternative.
Renin inhibition
In preclinical studies, the DRI aliskiren has been shown 
to have organ protective effects.60–63 Recent clinical end 
point trials indicate that aliskiren might also have end organ 
protective effects similar to ACE-I and ARBs in high risk 
patients.
Several placebo-controlled trials have assessed the anti-
hypertensive effects of aliskiren.59,64–68 In these trials, aliskiren 
was found to be both effective and well tolerated. The blood 
pressure lowering effect in these trials was comparable or 
greater than those seen in other trials of hydrochlorothiazides, 
irbesartan and amlodipine. The results of major clinical trials 
of aliskiren are summarized in Table 1.
A few studies have compared the blood pressure lower-
ing effect of aliskiren with other antihypertensive agents.68–74 
Pool et al68 investigated the blood pressure lowering effect 
of aliskiren alone or in combination with valsartan in a 
randomized clinical trial including 1123 patients with mild 
to moderate hypertension (msDBP  95 mmHg). They found 
both aliskiren and valsartan to produce dose-related reduction 
in both systolic and DBP in doses ranging from 75 to 300 mg 
and 80 to 320 mg respectively. The co-administration of 
aliskiren and valsartan produced a greater antihypertensive 
effect than either agent alone and comparable to valsartan/
hydrochlorothiazide, with similar tolerability compared to 
the component monotherapies and to placebo.
Oparil et al conducted a randomized clinical trial71 of 1797 
hypertensive patients (msDBP 95–109 mmHg) treated with 
either aliskiren 150 mg od, valsartan 160 mg od, a combination 
of the two or placebo for 4 weeks. Thereafter, forced titra-
tion was made to the double doses for another 4 weeks. The 
combination of aliskiren/valsartan 300/320 mg lowered the 
mean seated DBP from baseline by 12.2 mmHg, that was 
signifi cantly more than for placebo or either monotherapy 
(9.0 and 9.7 mmHg for aliskiren and valsartan respectively, 
p  0.0001). The aliskiren/valsartan combination also low-
ered mean seated SBP (msSBP) signifi cantly by 17.2 mmHg 
as compared to aliskiren (13.0 mmHg) and valsartan 
(12.8 mmHg) treatment respectively, p  0.0001). Rates of 
adverse events were similar in all groups.
Dahlöf et al75 performed a meta-analysis of 8481 patients 
included in placebo controlled trials with aliskiren as active 
treatment. The blood pressure lowering effects of aliskiren 
150 and 300 mg od were 12.5/10.1 and 15.2/11.8 mmHg 
respectively from baseline compared to 6.2/5.9 mmHg for 
placebo (p  0.0001).
In a study of obese hypertensive patients (ms DBP 
95–109 mmHg, body mass index 30 kg/m2 or higher), not 
responsive to hydrochlorothiazide monotherapy,70 Jordan 
et al compared the effect of aliskiren, irbesartan, amlodipine 
or placebo as add on treatment in conventional doses. After 
8 weeks of treatment the aliskiren/hydrochlorothiazide 
300/25 mg combination resulted in a 15.8/11.9 mmHg 
lowering of blood pressure that was similar to those 
obtained by irbesartan/hydrochlorothiazide 300/25 mg and 
amlodipine/hydrochlorothiazide 10/25 mg. The tolerability 
of aliskiren/hydrochlorothiazide was similar to that of 
placebo/hydrochlorothiazide.
In a dose escalating study, Stanton et al72 compared the 
effects of aliskiren (37.5–300 mg od) to that of losartan 
100 mg in 226 patients with mild to moderate hypertension 
(mean daytime ambulatory SBP  140 mmHg) during 4 
weeks of treatment. Dose-dependent reductions were seen 
in systolic ambulatory blood pressure and plasma renin 
activity, but the blood pressure lowering effects of aliskiren 
(75–300 mg) were not signifi cantly different from those of 
losartan 100 mg.
The antihypertensive effect and safety of aliskiren 150 to 
300 mg was compared to that of ramipril 5 to 10 mg both as 
monotherapy and combination of the two in a randomized 
trial of 837 diabetic patients with hypertension (msDBP 
96–109 mmHg).73 Aliskiren was well tolerated either as 
monotherapy or combination with ramipril. After 8 weeks 
of treatment the patients receiving combination treatment 
had 4.6/2.1 mmHg lower mean blood pressure than either 
monotherapy.
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A randomized study74 compared the efficacy and 
tolerability of aliskiren-based therapy with ramipril-
based therapy among 846 hypertensive patients (msDBP 
95–109 mmHg) during 6 months of treatment. Aliskiren 
was given 150 to 300 mg with ramipril 5 to 10 mg as an 
active comparator. Hydrochlorothiazide 12.5 to 25 mg was 
added in each arm in case of inadequate blood pressure 
control. Aliskiren provided signifi cantly better blood pressure 
reduction (msSBP 17.9 vs 15.2 mmHg, p = 0.0036, mDBP 
13.2 vs 12.0 mmHg, p = 0.025) and resulted in higher rates 
of blood pressure control (61.4% vs 53.0%, p = 0.0205).
Similar results were seen in a trial comparing aliskiren 
150 mg with atenolol 50 mg.69 After 12 weeks of treatment 
the blood pressure lowering effects of both agents were 
similar (14.3/11.3 vs 14.3/11.7 mmHg respectively) although 
the combination of both was more effective than either 
monotherapy (17.3/14.1 mmHg).
These studies confi rm that aliskiren, either alone or in 
several combinations, is well tolerated and has blood pressure 
lowering effects similar to the diverse comparators. However, 
these trials did not focus on end organ protection and typically 
included patients 50–55 years of age.
End organ protection with aliskiren
In the AVOID trial76 599 patients with type 2 diabetes 
mellitus and hypertension with nephropathy, were studied 
in a double blind randomized trial. They were optimally 
treated with antihypertensive medication including losartan 
100 mg od and received in addition aliskiren vs placebo. 
At baseline, the mean seated blood pressure was relatively 
well controlled (135/78 mmHg). The primary end point was 
decrease in urinary albumin to creatinin ratio (UACR) after 
6 months of treatment. The primary end point was reduced 
by 20% (p  0.001) in the aliskiren group as compared to 
placebo and reduction of more than 50% in UACR was 
seen signifi cantly more often in the aliskiren group (24.7%) 
than in the placebo group (12.5%). This antiproteinuric 
effect was reached in the aliskiren-treated patients although 
the reductions in mean SBP (2 mmHg, p = 0.07) and DBP 
(1 mmHg, p = 0.08) were only marginal. It was concluded 
that aliskiren might have renoprotective effects that were 
independent of its blood pressure lowering effects in patients 
with diabetes and hypertension with nephropathy who are 
receiving recommended renoprotective treatment.
The Aliskiren Observation of Heart Failure Treatment 
(ALOFT) investigators studied the effects of adding aliskiren 
to an ACE-I in patients with heart failure.77 Patients (n = 302) 
with New York Heart Association II–IV heart failure and 
current or past history of hypertension were included in a 
randomized double blind trial. Three months treatment of 
aliskiren 150 mg or placebo was added to a previous regimen 
of ACE-I (or ARB) and beta-blocker. The mean age of the 
patients was 68 years and their mean left ventricular ejection 
fraction was 31%. The mean seated blood pressure at study 
entry was 129/77 mmHg. The systolic BP did not change 
signifi cantly between treatment groups, but there was a 
marginal effect of msDBP lowering (2.9 vs 0.2 mmHg, 
p = 0.06) for aliskiren vs placebo respectively. The mean 
N-terminal pro-BNP level was approximately 2100 pg/mL at 
baseline. The plasma N-terminal pro-BNP rose by 762 (± 6123) 
pg/mL in the placebo group and fell by 244 (±2015) pg/mL 
in the aliskiren group after 12 weeks of treatment. Total BNP 
and urinary aldosterone were also reduced by aliskiren. It was 
concluded that addition of aliskiren to an ACE-I (or ARB) 
and beta-blocker had favorable neurohormonal effects in heart 
failure and appeared to be well tolerated.
The ALLAY study focused on the effects of aliskiren 
alone or in combination with losartan compared to losartan 
alone in the reduction of left ventricular hypertrophy among 
460 overweight hypertensive patients with left ventricular 
hypertrophy.78 This study showed that aliskiren reduced left 
ventricular hypertrophy as effectively as losartan (–5.4% 
vs –4.7%, p = ns). However no effect on the primary end point 
was reached in this study as the combination of the two agents 
was not signifi cantly more effective than each monotherapy 
alone in reducing left ventricular hypertrophy. The decrease 
in left ventricular hypertrophy turned out to be directly related 
to the level of blood pressure reduction achieved. However, at 
baseline the blood pressure was approximately 145/89 mmHg 
and was similarly reduced in all treatment groups (aliskiren 
group by 6.5/3.8 mmHg, losartan group by 5.5/3.7 mmHg 
and aliskiren/valsartan combination group by 6.6/4.6 mmHg, 
p = ns). The lack of difference between treatment arms might 
be due to the fact that additional treatment was allowed to 
reach treatment targets in all groups.
Aliskiren and the elderly
The safety and tolerability of aliskiren was studied in 
355 elderly patients (65 years or older) with systolic hyper-
tension (msSBP 145–179 mmHg or mean ambulatory SBP 
135 mmHg or higher).79 After 8 weeks of treatment aliskiren 
doses of 75, 150 and 300 mg and lisinopril 10 mg lowered 
mean ambulatory SBP by 8.4, 7.1, 8.7 and 10.2 mmHg 
respectively. Mean ambulatory DBP was lowered by 4.5; 
3.6; 3.9 and 6.3 mmHg respectively. All treatment groups 
lowered msSBP and msDBP significantly compared to 
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Table 1 Major clinical trials of aliskiren
Reference Publication 
year
Number 
of patients
Treatment Main results
Gradman et al64 2005 652 Aliskiren 150–600 
Irbesartan 150 
Placebo
Dose ranging study, all aliskiren doses 
showing signifi cant effect on SBP and DBP 
compared to placebo. Plateau at 300 mg 
aliskiren with similar effect of aliskiren 
150 mg and irbesartan 150 mg
Villamil et al65 2007 2776 Aliskiren 75–300 
HCTZ 6.25–25 
Aliskiren/HCTZ 75–300/6.25–25
Dose ranging study, all aliskiren doses 
showing signifi cant dose-dependent effect 
on DBP compared to placebo. Aliskiren 
150–300 mg, all HCTZ doses and all 
combinations superior to placebo in SBP 
effect. Aliskiren lowered PRA
Oh et al66 2007 672 Aliskiren 150–600 
Placebo
Dose ranging study, all aliskiren doses 
showing signifi cant dose-dependent effect 
on SBP and DBP compared to placebo. 
Aliskiren resulted in PRA reductions and 
increased PRC
Kushiro et al67 2006 455 Aliskiren 75–300 
Placebo
Aliskiren produced a signifi cant and 
dose-dependent reduction in SBP and 
DBP compared to placebo. Placebo-like 
tolerability of aliskiren
Pool et al68 2007 1123 Aliskiren 75–300 
Valsartan 80–320 
Aliskiren/valsartan 75–300/80–320 
Valsartan/HCTZ 160/12.5 
Placebo
Aliskiren and valsartan both produced 
dose-related reductions in SBP and DBP. 
Co-administration more effective than 
either monotherapy and comparative 
to valsartan/HCTZ. Well tolerated
Dietz69 2008 694 Aliskiren 150 
Atenolol 50
Similar blood pressure reduction with 
aliskiren and atenolol. Combination was 
more effective than either monotherapy
Jordan et al70 2007 490 Aliskiren 150-aliskiren/HCTZ 300/25 
Irbesartan 150-irbesartan/HCTZ 
300/25 
Amlodipine 5-amlodipine/HCTZ 
10/25 
Placebo/HCTZ 25
BP lowering similar for aliskiren/HCTZ 
as for irbesartan/HCTZ and amlodipine/
HCTZ. Aliskiren/HCTZ tolerated similar 
to placebo/HCTZ
Oparil S et al71 2007 1797 Aliskiren 150–300 
Valsartan 160–320 
Aliskiren/valsartan 150/160–300/320 
Placebo
Combination of aliskiren and valsartan 
more effective in reducing both SBP and 
DBP than either monotherapy alone
Stanton et al72 2003 226 Aliskiren 37.5–300 
Losartan 100
Similar dose-dependent reduction in ABPM 
for aliskiren and losartan
Uresin et al73 2007 837 Aliskiren 150–300 
Ramipril 5–10 
Aliskiren/ramipril 5/150–10/300
Patients with diabetes. Aliskiren well 
tolerated either alone or in combination 
with ramipril. Combination treatment 
reduced BP 4.6/2.1 over monotherapy
Andersen et al74 2008 842 Aliskiren 150–300 (HCTZ 12.5–25) 
Ramipril 5–10 (HCTZ 12.5–25)
Aliskiren provided signifi cantly better SBP 
and DBP reduction and higher rates of BP 
control than ramipril-based therapy
Dahlöf75 2007 8481 Aliskiren 150–300 
Placebo (meta-analysis)
Aliskiren 150 and 300 mg treatment 
resulted in a signifi cant 12.5/10.1 and 
15.2/11.8 mmHg lowering in BP compared 
to 6.2/5.9 mmHg for placebo
(Continued)
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Table 1 (Continued)
Reference Publication 
year
Number 
of patients
Treatment Main results
Parving H-H et al76 
AVOID trial
2008 599 Aliskiren 150–300 
Placebo
Pts with diabetes and nephropathy 
optimally treated with losartan at baseline. 
UACR reduced 20% by aliskiren treatment 
compared to placebo without signifi cant 
reductions in BP. UACR reduction of 
50% or more was seen twice as often in 
aliskiren group
McMurray et al77 
ALOFT
2008 302 Aliskiren 150 
Placebo
Pts with CHF and HT on baseline 
treatment with ACE-I (or ARB) and 
beta-blocker.  Aliskiren was well tolerated 
and showed favorable neurohormonal 
effects (pro-BNP lowering)
Solomon et al78 
ALLAY
2008 460 Aliskiren 
Losartan 
Aliskiren/losartan
Aliskiren and losartan equally effective in 
reducing left ventricular hypertrophy, with 
no additional effect from combination 
therapy
Verdecchia et al79 2007 355 Aliskiren 75–300 
Lisinopril 10
Elderly population (65 years and older) 
with HT.  Aliskiren was well tolerated.  All 
treatment groups lowered mean seated 
SBP and DBP compared to baseline
Schmieder et al80 2008 1124 Aliskiren 300 (amlodipine 5–10) 
HCTZ 25 (amlodipine 5–10)
Post-hoc analysis comparing elderly and 
very elderly to younger pts with HT. After 
52 weeks aliskiren provided signifi cantly 
greater reductions in SBP and PP among 
elderly and very elderly as compared to 
younger pts. Aliskiren was well tolerated 
and more effective than HCTZ
Yarows et al81–82 2008 1797 Aliskiren 
Valsartan 
Aliskiren/valsartan
Subgroup analysis comparing elderly with 
younger patients. Aliskiren monotherapy 
and aliskiren/valsartan combinations were 
equally well tolerated in elderly as in 
younger pts. Combination treatment more 
effective than monotherapy in SBP lower-
ing and control rates among elderly pts
Gradman et al83 2008 776 Aliskiren 150 
Aliskiren 300 
Placebo
Pooled analysis of 8 RCTs comparing effi -
cacy of aliskiren among elderly vs younger 
pts with HT.  Aliskiren 150 and 300 mg 
lowered BP signifi cantly compared with 
placebo independent of age in pts with 
hypertension
Duprez et al84 
AGELESS
2008 900 Aliskiren 150–300 (HCTZ 12.5–25) 
(amlodipine 5–10) 
Ramipril 5–10 (HCTZ 12.5–25) 
(amlodipine 5–10)
Dose escalating study of aliskiren-HCTZ-
amlodipine vs ramipril-HCTZ-amlodipine 
among elderly pts with HT.  Aliskiren-based 
therapy was superior to ramipril-based 
therapy at 12 weeks and non-inferior
at 36 weeks in msSBP lowering.  A higher 
control rate and less need for add-on 
therapy was seen for aliskiren compared 
with ramipril therapy
Abbreviations: ABPM, ambulatory blood pressure monitoring;  ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, brain natriuretic 
peptide; BP, blood pressure; CHF, congestive heart failure; HCTZ, hydrochlorothiazide; HT, hypertension; DBP, diastolic blood pressure; SBP, systolic blood pressure; msSBP, 
mean seated systolic blood pressure; PRA, plasma renin activity; PRC, plasma renin concentration; PP, pulse pressure; RCTs, randomized clinical trials; UACR, urinary albumin 
to creatinine ratio.
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baseline and the proportion of patients that reached blood 
pressure control (140/90 mmHg) with aliskiren 300 mg 
was greater than with aliskiren 75 mg (36.2% vs 24.2%, 
p = 0.033). Importantly, there was no evidence of dose-
related increases in the incidence of adverse events in this 
elderly population.
In a post-hoc analysis of a double blind randomized trial, 
Schmieder et al80 studied the blood pressure lowering effect 
of aliskiren 300 mg vs hydrochlorothiazide 25 mg in 1124 
elderly (65 years) and very elderly (75 years) patients 
with hypertension. Amlodipine 5 to 10 mg was added as 
needed to reach target blood pressure of 140/90. After 
52 weeks aliskiren based treatment provided signifi cantly 
greater reductions in SBP and pulse pressure among the 
elderly and very elderly patients than in younger patients 
(p  0.05). Blood pressure control rates were greater with 
aliskiren-based therapy than with hydrochlorothiazide 
therapy in the elderly and aliskiren was well tolerated. This 
study indicates that aliskiren is well tolerated in elderly and 
very elderly patients and is more effective than thiazide 
diuretics in lowering systolic hypertension and elevated 
pulse pressure.
In another subgroup analysis81,82 of a randomized double 
blind trial including 1797 patients with hypertension, 
Yarrows et al studied the effect of aliskiren, valsartan and the 
combination of both in elderly patients compared to those 
younger than 65 years of age. Aliskiren monotherapy and 
aliskiren/valsartan combinations were equally well tolerated 
in the elderly as in younger patients. The combination pro-
vided greater reductions in SBP and blood pressure control 
rates than did valsartan monotherapy in the elderly patients. 
The effect of aliskiren/valsartan and high dose valsartan on 
pulse pressure was greater in elderly patients than in younger 
patients.
In a pooled analysis of 8 randomized clinical trials of 
hypertensive patients (msDBP 95–109 mmHg) treated with 
aliskiren Gradman et al83 found aliskiren to provide effec-
tive blood pressure reductions and improve responder rates 
compared with placebo, and independent of age.
Finally, the AGELESS study,84 presented at the American 
Heart Association 2008 Scientifi c Sessions, was a randomized 
trial of hypertensive patients, 65 years of age and older. Nine 
hundred and one patients received either aliskiren 150 mg 
od or ramipril 5 mg od for 4 weeks. If the treatment goal 
of 140 mmHg SBP was not reached at 4 weeks, the doses 
were doubled. At 12 weeks, hydrochlorothiazide 12.5 to 
25 mg could be added, followed by amlodipine 5 to 10 mg 
daily. The mean age of the study population was 72 years 
and 53% were females. Patients 75 years or older made up 
32.5% of the population. The incidence of adverse events 
was similar between groups. At 12 weeks end point aliskiren 
treatment resulted in a signifi cantly greater reduction of 
SBP than ramipril (13.6 vs 11.3 mmHg, p  0.0001) (mean 
difference –2.32 mmHg, 95% CI –4.34 to 0.30, p = 0.0421). 
At the 36-week end point, aliskiren-based treatment was non-
inferior to ramipril based treatment although the difference 
(–1.92, 95% CI –4.03 to 0.19, p = 0.0747) did not reach 
statistical signifi cance.
In summary, renin inhibition with aliskiren has been 
shown to be at least equally effective for blood pressure 
lowering as ramipril, losartan, valsartan, lisinopril, atenolol 
and hydrochlorothiazide both as monotherapy and in 
combinations. Aliskiren has shown some organ protective 
effects and is well tolerated and effective in both elderly 
hypertensive as well as hypertensive patients in general.
Conclusion
High blood pressure is a major risk factor for cardiovascular 
and renal complications. This risk is especially well estab-
lished in the elderly population. Contrary to earlier belief, 
a number of clinical trials have shown blood pressure treat-
ment to be both safe and effective in end organ protection in 
elderly patients. Most of the elderly will need combination 
therapy to control their blood pressure and achieve optimal 
end organ protection. Recent trials indicate that agents 
blocking the RAAS might be more effective for this purpose 
through diverse pleiotropic effects. Calcium channel block-
ers, being both well tolerated, safe and effective for blood 
pressure control, remain fi rst-line drugs in the treatment of 
hypertension in elderly patients, especially in combinations 
with inhibitors of the RAAS. Thiazide diuretics still have 
their place as fi rst-line agents in blood pressure control as 
they are both inexpensive, effective and well tolerated. The 
DRI aliskiren has been shown to have at least comparable 
blood pressure lowering effects as other RAAS inhibitors, 
and a few early clinical trials indicate that it may provide 
a signifi cant benefi t in combination with other agents for 
end organ protective effects. Aliskiren has some theoretical 
advantages that could contribute to its end organ protection. 
However, upcoming randomized clinical trials will have to 
determine whether these effects translate into a signifi cant 
clinical benefi t to reduce end organ damage in the elderly 
population.
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